174 related articles for article (PubMed ID: 9222509)
1. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds.
Zapp ML; Young DW; Kumar A; Singh R; Boykin DW; Wilson WD; Green MR
Bioorg Med Chem; 1997 Jun; 5(6):1149-55. PubMed ID: 9222509
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives.
Ratmeyer L; Zapp ML; Green MR; Vinayak R; Kumar A; Boykin DW; Wilson WD
Biochemistry; 1996 Oct; 35(42):13689-96. PubMed ID: 8885849
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.
Xiao G; Kumar A; Li K; Rigl CT; Bajic M; Davis TM; Boykin DW; Wilson WD
Bioorg Med Chem; 2001 May; 9(5):1097-113. PubMed ID: 11377168
[TBL] [Abstract][Full Text] [Related]
4. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
DeJong ES; Chang CE; Gilson MK; Marino JP
Biochemistry; 2003 Jul; 42(26):8035-46. PubMed ID: 12834355
[TBL] [Abstract][Full Text] [Related]
5. A heterocyclic inhibitor of the REV-RRE complex binds to RRE as a dimer.
Li K; Davis TM; Bailly C; Kumar A; Boykin DW; Wilson WD
Biochemistry; 2001 Feb; 40(5):1150-8. PubMed ID: 11170440
[TBL] [Abstract][Full Text] [Related]
6. RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element.
Luedtke NW; Liu Q; Tor Y
Biochemistry; 2003 Oct; 42(39):11391-403. PubMed ID: 14516190
[TBL] [Abstract][Full Text] [Related]
7. An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction.
Mills NL; Daugherty MD; Frankel AD; Guy RK
J Am Chem Soc; 2006 Mar; 128(11):3496-7. PubMed ID: 16536504
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.
Olsen HS; Cochrane AW; Dillon PJ; Nalin CM; Rosen CA
Genes Dev; 1990 Aug; 4(8):1357-64. PubMed ID: 2227413
[TBL] [Abstract][Full Text] [Related]
9. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production.
Zapp ML; Stern S; Green MR
Cell; 1993 Sep; 74(6):969-78. PubMed ID: 8402886
[TBL] [Abstract][Full Text] [Related]
10. A dynamic in vivo view of the HIV-I Rev-RRE interaction.
Charpentier B; Stutz F; Rosbash M
J Mol Biol; 1997 Mar; 266(5):950-62. PubMed ID: 9086273
[TBL] [Abstract][Full Text] [Related]
11. Design and analysis of RNA structure-specific agents as potential antivirals.
Wilson WD; Ratmeyer L; Zhao M; Ding D; McConnaughie AW; Kumar A; Boykin DW
J Mol Recognit; 1996; 9(2):187-96. PubMed ID: 8877812
[TBL] [Abstract][Full Text] [Related]
12. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region.
Wang Y; Hamasaki K; Rando RR
Biochemistry; 1997 Jan; 36(4):768-79. PubMed ID: 9020774
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the HIV-1 Rev Response Element during Natural Infection Reveals Nucleotide Changes That Correlate with Altered Structure and Increased Activity over Time.
Sherpa C; Jackson PEH; Gray LR; Anastos K; Le Grice SFJ; Hammarskjold ML; Rekosh D
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867301
[TBL] [Abstract][Full Text] [Related]
14. Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.
Nam YS; Petrovic A; Jeong KS; Venkatesan S
J Virol; 2001 Mar; 75(6):2957-71. PubMed ID: 11222721
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human immunodeficiency virus type 1 Rev-Rev-response element complex formation by complementary oligonucleotides.
Chin DJ
J Virol; 1992 Jan; 66(1):600-7. PubMed ID: 1727504
[TBL] [Abstract][Full Text] [Related]
16. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein.
Tiley LS; Malim MH; Tewary HK; Stockley PG; Cullen BR
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):758-62. PubMed ID: 1731351
[TBL] [Abstract][Full Text] [Related]
17. The human immunodeficiency virus type 1 Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5' splice site in a 3' untranslated region.
Barksdale SK; Baker CC
Mol Cell Biol; 1995 Jun; 15(6):2962-71. PubMed ID: 7760794
[TBL] [Abstract][Full Text] [Related]
18. Interaction of HIV Rev peptides with the Rev response element RNA.
Williamson JR; Battiste JL; Mao H; Frankel AD
Nucleic Acids Symp Ser; 1995; (33):46-8. PubMed ID: 8643394
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the HIV-1 Rev protein and its target sequence, the Rev responsive element.
Olsen HS; Beidas S; Dillon P; Rosen CA; Cochrane AW
J Acquir Immune Defic Syndr (1988); 1991; 4(6):558-67. PubMed ID: 2023097
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy.
Lacourciere KA; Stivers JT; Marino JP
Biochemistry; 2000 May; 39(19):5630-41. PubMed ID: 10801313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
